MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why NVCR Stock dropped -7.48% Today — RQD Quant Desk Flash
$13.11 -7.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $12.91
NovoCure Limited (NVCR) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $1.53B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $12.91 (-1.54%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-15.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NVCR)Realized 20D OHLCV Swing Band: ±11.4%
Deterministic 5-Pillar Attribution (24/100 Composite)
🔍 WHY NVCR SCORES 24/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (33% of score)
Altman Z-Score 0.54 (DISTRESS RISK (<1.8)) • Piotroski F-Score 6/9
▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (29% of score)
FRED Regime × Technicals: 28% of 52W Range • RSI-14 at 34 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$14.58-3.5% Next Q
32
Q2 (-2Q)Grade E$14.07+4.3% Next Q
29
Q3 (-1Q)Grade E$14.68-10.7% Next Q
27
CurrentGrade E$13.11-10.9% Hist 90D α
24
Trajectory: E (32) → E (24)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NVCR Turnaround Squeeze
While NVCR currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($15.79) and Max Pain ($13.77) forces dealer call-delta covering toward $22.52.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NVCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NVCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NVCR Stock dropped -7.48% Today — RQD Quant Desk Flash
NovoCure Limited (NVCR) dropped -7.48% to $13.11, trading at 28% of its 52-week range ($9.82 – $21.45). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 28% of its 52-week range ($9.82 – $21.45) with RSI-14 at 34 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.4% around $13.11 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 74.5% gross margin and $0 annual free cash flow.
Live NVCR Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NVCR)
- ✓Walkthrough of NVCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NVCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.81%🛡️ HOLDING TREND SUPPORT
2026-10-30O $12.81H $13.26L $12.52C $13.11VOL 1.97M
RES: $15.58SUP: $12.90SMA50: $15.79SMA200: $14.82
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NVCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +8.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NVCR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NVCR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NVCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NVCR)
Health Care Rank #993 of 1016
⚔️ TNDM vs NVCR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NVCR vs. TNDM, ATEC, KMTS, BVS)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, NovoCure Limited (NVCR) ranks #993 by composite RQD confidence (24/100, grade E) and #304 by equity capitalization ($1.53B). Within this direct 5-issuer industry benchmark cohort, BVS leads on earnings valuation at 55.0x trailing P/E, while BVS leads on capital efficiency and profitability with 10.4% ROIC and 68.3% gross margin. BVS currently holds the highest overall quantitative score in the immediate peer group at 66/100 (C+) compared with NVCR at 24/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NVCR
ACTIVE
NovoCure Limited | E | 24/100 | — | 74.5% | -27.5% | -7.48% | $1.53B | Benchmark Subject |
| TNDM Tandem Diabetes Care Inc. | D- | 35/100 | — | 53.8% | -35.0% | +0.56% | $1.38B | /tndm-vs-nvcr → |
| ATEC Alphatec Holdings Inc. | D- | 38/100 | — | 69.6% | -18.4% | -0.70% | $1.76B | /atec-vs-nvcr → |
| KMTS Kestra Medical Technologies Ltd. | D- | 43/100 | — | 51.4% | -35.0% | +2.48% | $1.82B | /kmts-vs-nvcr → |
| BVS Bioventus Inc. (Class A) | C+ | 66/100 | 55.0x | 68.3% | 10.4% | +1.50% | $1.25B | /bvs-vs-nvcr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001645113In its most recent audited fiscal period (FY2025, filed 2025-12-31), NovoCure Limited (NVCR) reported GAAP revenue of $655.4M (+8.3% vs. FY2024 revenue of $605.2M , and +28.7% cumulative change since FY2023) , GAAP net income of -$136.2M, operating cash flow of -$49.0M, and free cash flow of -$75.7M (-9.3% YoY). On the balance sheet, NVCR closed FY2025 with $804.3M in total assets against $195.0M in total debt (Altman Z-Score: 0.54, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $655.4M | -$136.2M | -$49.0M | -$75.7M | $804.3M | $195.0M |
| FY2024 (FY) | 2024-12-31 | $605.2M | -$169.0M | -$26.4M | -$69.2M | $1.24B | $97.3M |
| FY2023 (FY) | 2023-12-31 | $509.3M | -$207.0M | -$73.3M | -$73.3M | — | — |
3. NVCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NVCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, NovoCure Limited (NASDAQ: NVCR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $13.11 (-7.48% 1D, market cap $1.53B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NVCR ranks #993 in composite RQD confidence.
How does NVCR compare to TNDM and ATEC in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), NVCR carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 74.5%, and ROIC of -27.5%. By comparison, TNDM (Tandem Diabetes Care Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.38B) and ATEC (Alphatec Holdings Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -18.4%, cap $1.76B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NVCR?
Per NVCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001645113), NovoCure Limited generated $655.4M in revenue (+8.3% YoY), -$136.2M in net income, and -$75.7M in free cash flow against $804.3M in total assets and $195.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NVCR trading relative to its 50-day, 200-day, and 52-week technical levels?
NVCR last traded at $13.11 (-7.48% on volume of 5,956,150 shares), positioning the stock -16.97% below its 50-day simple moving average ($15.79) and -11.54% below its 200-day simple moving average ($14.82). Across its 52-week range of $9.82 to $21.45, NVCR sits at the 28.3% percentile with a 14-day RSI of 34.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.4% ($11.62 to $14.60).
NVCR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NVCR stock moving today?
Why NVCR Stock dropped -7.48% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.